Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Short-Term Debt issuances (2021 - 2025)

Aytu Biopharma (AYTU) has disclosed Short-Term Debt issuances for 5 consecutive years, with -$5.8 million as the latest value for Q4 2025.

  • Quarterly Short-Term Debt issuances fell 2147.29% to -$5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Dec 2025, up 69.56% year-over-year, with the annual reading at $6.7 million for FY2025, 701.44% up from the prior year.
  • Short-Term Debt issuances for Q4 2025 was -$5.8 million at Aytu Biopharma, down from $5.8 million in the prior quarter.
  • The five-year high for Short-Term Debt issuances was $42.2 million in Q3 2021, with the low at -$43.0 million in Q4 2021.
  • Average Short-Term Debt issuances over 5 years is $63388.9, with a median of $119500.0 recorded in 2022.
  • The sharpest move saw Short-Term Debt issuances tumbled 2165.42% in 2023, then soared 983.96% in 2025.
  • Over 5 years, Short-Term Debt issuances stood at -$43.0 million in 2021, then soared by 98.47% to -$658000.0 in 2022, then soared by 71.28% to -$189000.0 in 2023, then crashed by 36.51% to -$258000.0 in 2024, then tumbled by 2147.29% to -$5.8 million in 2025.
  • According to Business Quant data, Short-Term Debt issuances over the past three periods came in at -$5.8 million, $5.8 million, and -$965000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.